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ess: vjain@ucsd.edu (V.Summary Histoplasma capsulatum (HC) is a thermally dimorphic ascomycete that
is a significant cause of respiratory infections (480%) in endemic areas (Midwest and
southeast USA), but infections are rare in non-endemic areas. Most primary HC
infections are subclinical or self-limited. While reactivation Histoplasmosis has been
reported in the setting of immunosuppression, it remains unclear whether remote
primary latent infection represents risk of endogenous reactivation after anti-tumor
necrosis factor (TNF)-a therapy [Yusuf H, Craig GT, Allan D. Disseminated
histoplasmosis presenting with oral lesions—report of a case. Br J Oral Surg
1979;16(3):234–40; Catanzaro A, Spitler LE, Campbell GD, Moser KM. Transfer
factor therapy for histoplasmosis in a patient with Hodgkin’s disease. Arch
Intern Med 1981;141(4):533–7; Fredricks DN, Rojanasthien N, Jacobson MA. AIDS-
related disseminated histoplasmosis in San Francisco, California. West J Med
1997;167(5):315–21]. We report a case of a patient who developed reactivation
Histoplasmosis after receiving anti-TNF-a. To our knowledge, this is the first clear
report of reactivation of ‘‘latent’’ Histoplasmosis after anti-TNF-a therapy.
& 2005 Elsevier Ltd. All rights reserved.Case report
Our patient is a 40-year old man with a history
of Crohn’s disease being treated with infliximabElsevier Ltd. All rights reserv
sulatum; IL, Interleukin;
of Internal Medicine, Uni-
e, Fresno, CA 93702, USA.
V. Jain).(anti-TNF-a therapy) and intermittent prednisone
for approximately one year. He presented with
cough minimally productive of clear to whitish
sputum, shortness of breath, a 10-lb weight loss
over the previous 6 weeks, fevers and night sweats.
He had traveled to an area endemic for Histoplas-
ma capsulatum (HC) 5 years prior to presentation,
but he denied travel outside of California in the last
5 years. On exam, he was in no respiratory distress
but had bilateral inspiratory crackles at both lunged.
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Figure 1 Proposed mechanism of reactivation reactiva-
tion: Anti-TNF-a therapy in Crohn’s disease may lead to
an unbiased increase in Th2 cytokines which may
V.V. Jain et al.1292bases. Laboratory studies revealed normal com-
plete blood count and liver function tests. Chest
X-ray demonstrated diffuse alveolar infiltrates
bilaterally. Transbronchial lung biopsy specimen
showed well-formed granuloma consisting of no-
dules of epithelioid histiocytes and lymphocytes
without evidence of multinucleated giant cells,
necrosis or vasculitis. Bronchoalveolar lavage grew
HC but was negative for acid-fast bacilli, Pneumo-
cystis carinii, cryptococcus, and coccidiomycosis.
Immune studies were negative for coccidiomycosis.
Anti-TNF-a therapy was held and the patient
responded well to itraconazole therapy.1–3reactivate histoplasmosis.Discussion
HC is a soil fungus endogenous to the southeastern
US, mid-Atlantic States, and the Ohio and Mis-
sissippi River Valleys.4 Primary infection with HC is
usually subclinical or self-limited but may present
as a fulminant infection in immunocompromised
patients. Animal models clearly demonstrate the
protective role for TNF-a in primary and secondary
infection, but the role of TNF-a in reactivation of
Histoplasmosis is not clear.5–7 Two previous reports
of Histoplasmosis in patients receiving either
infliximab or etanercept occurred in patients living
in endemic regions.8,9 While the time course of
Histoplasmosis after anti-TNF-a suggested reactiva-
tion,10 these patients could have experienced
reinfection. Mouse models have demonstrated that
anti-TNF increases the risk for reinfection.6 Our
patient is unique in that he had previously traveled
in an endemic area for HC, but denied travel outside
California for 5 years. Thus our case represents the
clearest evidence that TNF-a is important in
preventing reactivation of Histoplasmosis.
The T-cell immune response is divided into a TH1
response that generates interferon (IFN)-g and TNF-a
and a TH2 response that generates IL-4 and IL-10.
Both IL-4 and IL-10 have been investigated for their
protective role in Crohn’s disease.11,12 Presumably
anti-TNF-a exerts its beneficial effect on Crohn’s
disease by decreasing TNF-a levels directly or by
shifting the immune response from a TH1 to a TH2
predominance. Increased levels of IL-4 and IL-10
increase the risk for primary and secondary infec-
tion with HC and may contribute to increased risk
for reactivation Histoplasmosis. It has been demon-
strated previously that TNF-a plays a critical role in
mediating a protective response to secondary HC
infections in the absence of INF-g.2 Taken together,
these data suggest that T-cell derived TNF-a
(and INF-g) may play a critical role in inhibiting(or eradicating) HC infection over time after the
primary exposure, reducing the risk of reactivation.
Previous clinical experience and animal studies
have demonstrated that T-cells are important in
preventing reactivation in Histoplasmosis. Pre-
viously HC-infected patients with AIDS and markedly
decreased CD4 counts are at increased risk for
reactivation Histoplasmosis; and Histoplasmosis
reactivation has been described in a patient with
Hodgkin’s Disease.2 In a murine model of reactiva-
tion Histoplasmosis, the infection was reactivated
following depletion of CD4 and CD8 lymphocytes.13
These data support a role for T lymphocytes in
maintaining control of the primary infection, but do
not provide any additional mechanistic information.
Increased use of TNF antagonists have been
associated with increased frequency of some
granulomatous infections in patients treated with
these agents.10 While reactivation tuberculosis
following TNF blockade has been widely reported,
reactivating other infections such as coccidiomy-
cosis have not been reported. Our report provides
the most direct evidence of reactivation Histoplas-
mosis after anti-TNF therapy. Although the precise
mechanisms by which anti-TNF-a therapy causes
reactivation of HC need to be investigated, TNF-a
seems to be a central mediator of protective
immunity in HC infections (see Fig. 1).References
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